αβ and γδ T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients

Patients with end-stage organ failure benefit from recent advances in solid organ transplantation (SOT). Immunosuppressive medications are necessary to preserve long-term graft function and avoid rejection. On the downside, this predisposes patients to viral infections, reactivations, and virus-associated malignant complications. This review will focus on Epstein-Barr virus (EBV) as a risk for malignant transformation in immunosuppressed patients, as a target of the cellular immune response and new immunotherapeutic treatment options.

留言 (0)

沒有登入
gif